Hemostemix To Present At Life Science Investor Forum

(MENAFN- Newsfile Corp) Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCellTM (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that Chief Executive Officer Thomas Smeenk will present live at the Life Science Investor Forum on Thursday, September 18, 2025, at 12:00 p.m. ET .

Hemostemix has established itself as the world's #1 autologous stem cell therapy company, backed by:

• 11 peer-reviewed publications demonstrating safety and efficacy,
  
• 498 safe treatments completed to date ,
  
• Proven efficacy in no-option patients with severe angina , ischemic and non-ischemic dilated cardiomyopathy , and related co-morbidities , including congestive heart failure , peripheral arterial disease (PAD) , and chronic limb-threatening ischemia (CLTI) .

Mr. Smeenk's presentation will highlight the company's unparalleled clinical record and its expanding treatment opportunities. With the recent passage of Florida Senate Bill 1768 (SB 1768) , ACP-01 can now be legally offered to no-option patients in Florida-bringing hope and access to those who previously had no therapeutic path forward.

"ACP-01 is not science fiction-it is science fact. With 498 successful treatments, a strong body of peer-reviewed evidence, and commercial pathways open in Florida, Hemostemix is uniquely positioned to lead the global market for autologous stem cell therapy for cardiovascular diseases," said Thomas Smeenk, CEO of Hemostemix.

The Life Science Investor Forum is an interactive online event where institutional and individual investors can meet and ask questions in real time. Attendees are encouraged to log in ahead of the 12:00 p.m. ET presentation start.

Event Details

• Who: Thomas Smeenk, CEO, Hemostemix Inc.
  
• What: Live Presentation at Life Science Investor Forum
  
• When: Thursday, September 18, 2025 - 12:00 p.m. ET
  
• Where:

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCellTM (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease , chronic limb threatening ischemia , non ischemic dilated cardiomyopathy , ischemic cardiomyopathy , congestive heart failure , and angina . Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science . As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit .

MENAFN17092025004218003983ID1110073921